IP Library Granted Patent US 7,135,474
Granted Patent B2
US 7,135,474 · App. 10/514,909 · Granted Nov 14, 2006

Derivatives of 2-(1-benzyl-1H-pyrazolo(3,4-B)pyridine-3-yl)-5(-4-pyridinyl)l-4-pyrimidinamines and the use thereof as quanylate cyclase stimulators

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,135,474
App. No.
10/514,909
Granted
Nov 14, 2006
Kind
B2
Abstract

This application relates to compounds of the formula (I) in which R 1 is chlorine, cyano, trifluoromethyl or methoxy and R 2 is hydrogen or flurorine; or R 1 and R 2 are both fluorine; and to pharmaceutically acceptable salts of these materials. Pharmaceutical compositions containing these materials, and methods of using them in treatment of hypertension and sexual dysfunction are also disclosed and claimed.

Claims (21)

1. A compound of the formula (I)

in which

R 1 is chlorine, cyano, trifluoromethyl or methoxy, and

R 2 is hydrogen or fluorine, or

R 1 is fluorine, and

R 2 is fluorine,

or a pharmaceutically acceptable salt thereof.

2. The compound of the formula (Ia) as claimed in claim 1

in which

R 1a is selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

3. The compound of the formula (Ia) as claimed in claim 2 , in which

R 1a is

or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising at least one compound of the formula (I) as defined in claim 1 , and at least one further excipient.

5. A pharmaceutical composition comprising at least one compound of the formula (I) as defined in claim 1 in combination with at least one organic nitrate or NO donor.

6. A pharmaceutical composition comprising at least one compound of the formula (I) as defined in claim 1 in combination with at least one compound which inhibits the breakdown of cyclic guanosine monophosphate (cGMP).

7. A method for the treatment of hypertension, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 .

8. The method of claim 7 , where compounds of the formula (I) as defined in claim 1 are employed in combination with at least one organic nitrate or NO donor or in combination with at least one compound which inhibits the breakdown of cyclic guanosine monophosphate (cGMP).

9. A method for the treatment of sexual dysfunction, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 .

10. The method of claim 9 , wherein the sexual dysfunction is erectile dysfunction or female sexual dysfunction.

Assignments (3)
CHANGE OF NAME Recorded Apr 12, 2013
From: BAYER SCHERING PHARMA AG
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 030202/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2013
From: BAYER PHARMA AKTIENGESELLSCHAFT
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 029908/0217 →
MERGER Recorded Jan 12, 2010
From: BAYER HEALTHCARE AG
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 023769/0122 →